Tag Archives: Bristol

Bristol Myers, yielding to FDA pressure, pulls Opdivo in post-Nexavar liver cancer

Amid a regulatory campaign targeting immuno-oncology agents, Bristol Myers Squibb figured it’s probably futile to keep fighting the FDA on Opdivo’s shaky use in previously treated liver cancer. On Friday, Bristol Myers said it’s voluntarily withdrawing Opdivo’s approval in hepatocellular carcinoma patients who previously received Bayer’s standard-of-care Nexavar. The decision came about three months after… Read More »

Bristol Myers Squibb’s Opdivo cuts relapse risk in muscle-invasive bladder cancer

Bristol Myers Squibb’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease. The company revealed Thursday that its PD-1 fighter, against placebo, had lengthened the time muscle-invasive urothelial carcinoma patients could remain disease-free after surgery. All patients saw benefit,… Read More »

WCLC: Bristol Myers’ Opdivo-Yervoy duo slashes mesothelioma death risk by 26%

It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines. Saturday at the World Conference on Lung Cancer’s virtual presidential symposium, Bristol Myers unveiled phase 3 data showing the pair decreased the risk of death among previously untreated mesothelioma patients by 26%, helping them live… Read More »

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–May 15, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Pomalyst ® (pomalidomide) was approved by the U.S. Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are… Read More »

Big Pharma grounds employees: GSK, Bristol, Roche, Sanofi and more limit travel due to coronavirus

Biopharma companies are hunkering down as the COVID-19 epidemic breaks out worldwide. In a FiercePharma survey of biopharma companies late last month, most drugmakers said they were simply limiting travel to hard-hit countries such as China, South Korea and Italy. Now, as more cases pop up across the U.S., Europe and Asia, their tone has shifted. GlaxoSmithKline has “instructed all employees… Read More »